Get startedLog in
    Picture of Syros Pharmaceuticals logo

    SYRS — Syros Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    All News

    Brief: Syros Announces Completion Of Enrollment Necessary For Primary Endpoint Analysis In Phase 3 Trial

    Picture of Syros Pharmaceuticals logoSyros Pharmaceuticals
    25/03/2024 13:18
    March 25 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS ANNOUNCES COMPLETION OF ENROLLMENT OF 190 PATIENTS
NECESSARY TO SUPPORT PRIMARY ENDPOINT ANALYSIS IN SELECT-MDS-1
PHASE 3 TRIAL
    * SYROS PHARMACEUTICALS INC - ON TRACK TO REPORT PIVOTAL
COMPLETE
RESPONSE DATA BY MID-4Q 2024

Source text for Eikon:  ID:nBw30LknGa 
Further company coverage:  SYRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Syros Pharmaceuticals

    See all news